CTH 004
Alternative Names: CTH-004Latest Information Update: 23 Aug 2024
At a glance
- Originator Cartherics
- Developer Cartherics; Peter MacCallum Cancer Centre
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer